主营介绍

  • 产品类型:

    药品、医疗器械

  • 产品名称:

    注射用美罗培南 注射用头孢米诺钠 医疗器械

  • 经营范围:

    制造、销售(限本企业自产药品)片剂、硬胶囊剂(含抗肿瘤药)、颗粒剂、小容量注射剂、大容量注射剂、粉针剂(含头孢菌素类)及原料药(按许可证核定的产品项目从事生产经营),普通货运、危险货物运输(第2类第1、2项,第3类,第4类第1、2项,第5类第1项,第8类),生产、销售饲料添加剂、食品添加剂,销售五金、交电、化工产品及原料(不含化学危险品)、百货,建筑材料、装饰材料(不含危险化学品),钢材、木材、电器机械及器材、普通机械,制药技术咨询及转让,货物及技术进出口。

运营业务数据

最新公告日期:2018-04-21 
业务名称 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31
医药制造、药品流通产量(元) 1.08亿 1.05亿 - - -
医药制造、药品流通销量(元) 21.46亿 20.70亿 - - -
原料药(主要产品)销量(吨) - - 4690.00 7528.00 -
原料药(主要产品)产量(吨) - - 6936.00 8730.00 -
原料药(主要产品)销量(T) - - - - 8247.00
原料药(主要产品)产量(T) - - - - 8447.00

主营构成分析

{"2017-12-31":{"YYSR":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","171682.50"],["\u836f\u54c1\u5236\u9020\u4e1a","41667.19"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","85467.70"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","84231.32"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","41667.19"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","1983.49"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","213349.69"],["\u56fd\u5916",""]]},"YYCB":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","151369.36"],["\u836f\u54c1\u5236\u9020\u4e1a","6010.10"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","70516.84"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","77746.65"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","6010.10"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","3105.87"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","157379.46"],["\u56fd\u5916",""]]},"LRBL":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","36.29"],["\u836f\u54c1\u5236\u9020\u4e1a","63.71"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","26.71"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","11.59"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","63.71"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","-2.01"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","100.00"],["\u56fd\u5916",""]]}},"2017-06-30":{"YYSR":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","86243.29"],["\u836f\u54c1\u5236\u9020\u4e1a","18248.25"]],"2":[["\u836f\u54c1","48292.99"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","37750.98"],["\u5236\u5242\u836f","18248.25"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","199.33"]],"3":[["\u56fd\u5185","104491.54"]]},"YYCB":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","76337.41"],["\u836f\u54c1\u5236\u9020\u4e1a","5107.25"]],"2":[["\u836f\u54c1","45880.01"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","30329.91"],["\u5236\u5242\u836f","5107.25"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","127.49"]],"3":[["\u56fd\u5185","81444.66"]]},"LRBL":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","42.98"],["\u836f\u54c1\u5236\u9020\u4e1a","57.02"]],"2":[["\u836f\u54c1","10.47"],["\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","32.20"],["\u5236\u5242\u836f","57.02"],["\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","0.31"]],"3":[["\u56fd\u5185","100.00"]]}},"2016-12-31":{"YYSR":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","178030.84"],["\u836f\u54c1\u5236\u9020\u4e1a","26860.57"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","95275.57"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","82755.28"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","23540.55"],["\u836f\u54c1\u5236\u9020-\u539f\u6599\u836f","2355.34"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",964.68]],"3":[["\u56fd\u5185","202530.59"],["\u56fd\u5916","2360.82"]]},"YYCB":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","156579.10"],["\u836f\u54c1\u5236\u9020\u4e1a","9763.69"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","82107.86"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","74471.25"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","6220.21"],["\u836f\u54c1\u5236\u9020-\u539f\u6599\u836f","2372.30"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1171.19]],"3":[["\u56fd\u5185","163970.49"],["\u56fd\u5916","2372.30"]]},"LRBL":{"1":[["\u836f\u54c1\u6d41\u901a\u4e1a","55.65"],["\u836f\u54c1\u5236\u9020\u4e1a","44.35"]],"2":[["\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","34.16"],["\u836f\u54c1\u6d41\u901a-\u836f\u54c1","21.49"],["\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","44.93"],["\u836f\u54c1\u5236\u9020-\u539f\u6599\u836f","-0.04"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",-0.54]],"3":[["\u56fd\u5185","100.03"],["\u56fd\u5916","-0.03"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u836f\u54c1\u6d41\u901a\u4e1a","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[171682.5,86243.29,178030.84],"columnData":[80.47,82.54,86.89],"unit":["17.17\u4ebf","8.62\u4ebf","17.80\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020\u4e1a","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[41667.19,18248.25,26860.57],"columnData":[19.53,17.46,13.11],"unit":["4.17\u4ebf","1.82\u4ebf","2.69\u4ebf"]}],"chartWrap2":[{"name":"\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-12-31","2016-12-31"],"lineData":[85467.7,95275.57],"columnData":[40.06,46.5],"unit":["8.55\u4ebf","9.53\u4ebf"]},{"name":"\u836f\u54c1\u6d41\u901a-\u836f\u54c1","timeData":["2017-12-31","2016-12-31"],"lineData":[84231.32,82755.28],"columnData":[39.48,40.39],"unit":["8.42\u4ebf","8.28\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","timeData":["2017-12-31","2016-12-31"],"lineData":[41667.19,23540.55],"columnData":[19.53,11.49],"unit":["4.17\u4ebf","2.35\u4ebf"]},{"name":"\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","timeData":["2017-12-31","2017-06-30"],"lineData":[1983.49,199.33],"columnData":[0.93,0.19],"unit":["1983.49\u4e07","199.33\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-12-31","2016-12-31"],"lineData":[0,964.68],"columnData":[0,0.47],"unit":["0.00","964.68\u4e07"]},{"name":"\u836f\u54c1","timeData":["2017-06-30"],"lineData":[48292.99],"columnData":[46.22],"unit":["4.83\u4ebf"]},{"name":"\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-06-30"],"lineData":[37750.98],"columnData":[36.13],"unit":["3.78\u4ebf"]},{"name":"\u5236\u5242\u836f","timeData":["2017-06-30"],"lineData":[18248.25],"columnData":[17.46],"unit":["1.82\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020-\u539f\u6599\u836f","timeData":["2016-12-31"],"lineData":[2355.34],"columnData":[1.15],"unit":["2355.34\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[213349.69,104491.54,202530.59],"columnData":[100,100,98.85],"unit":["21.33\u4ebf","10.45\u4ebf","20.25\u4ebf"]},{"name":"\u56fd\u5916","timeData":["2017-12-31","2016-12-31"],"lineData":[0,2360.82],"columnData":[0,1.15],"unit":["0.00","2360.82\u4e07"]}]},"YYCB":{"chartWrap1":[{"name":"\u836f\u54c1\u6d41\u901a\u4e1a","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[151369.36,76337.41,156579.1],"columnData":[96.18,93.73,94.13],"unit":["15.14\u4ebf","7.63\u4ebf","15.66\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020\u4e1a","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[6010.1,5107.25,9763.69],"columnData":[3.82,6.27,5.87],"unit":["6010.10\u4e07","5107.25\u4e07","9763.69\u4e07"]}],"chartWrap2":[{"name":"\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-12-31","2016-12-31"],"lineData":[70516.84,82107.86],"columnData":[44.81,49.36],"unit":["7.05\u4ebf","8.21\u4ebf"]},{"name":"\u836f\u54c1\u6d41\u901a-\u836f\u54c1","timeData":["2017-12-31","2016-12-31"],"lineData":[77746.65,74471.25],"columnData":[49.4,44.77],"unit":["7.77\u4ebf","7.45\u4ebf"]},{"name":"\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","timeData":["2017-12-31","2016-12-31"],"lineData":[6010.1,6220.21],"columnData":[3.82,3.74],"unit":["6010.10\u4e07","6220.21\u4e07"]},{"name":"\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","timeData":["2017-12-31","2017-06-30"],"lineData":[3105.87,127.49],"columnData":[1.97,0.16],"unit":["3105.87\u4e07","127.49\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-12-31","2016-12-31"],"lineData":[0,1171.19],"columnData":[0,0.7],"unit":["0.00","1171.19\u4e07"]},{"name":"\u836f\u54c1","timeData":["2017-06-30"],"lineData":[45880.01],"columnData":[56.33],"unit":["4.59\u4ebf"]},{"name":"\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-06-30"],"lineData":[30329.91],"columnData":[37.24],"unit":["3.03\u4ebf"]},{"name":"\u5236\u5242\u836f","timeData":["2017-06-30"],"lineData":[5107.25],"columnData":[6.27],"unit":["5107.25\u4e07"]},{"name":"\u836f\u54c1\u5236\u9020-\u539f\u6599\u836f","timeData":["2016-12-31"],"lineData":[2372.3],"columnData":[1.43],"unit":["2372.30\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[157379.46,81444.66,163970.49],"columnData":[100,100,98.57],"unit":["15.74\u4ebf","8.14\u4ebf","16.40\u4ebf"]},{"name":"\u56fd\u5916","timeData":["2017-12-31","2016-12-31"],"lineData":[0,2372.3],"columnData":[0,1.43],"unit":["0.00","2372.30\u4e07"]}]},"LRBL":{"chartWrap1":[{"name":"\u836f\u54c1\u6d41\u901a\u4e1a","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[36.29,42.98,55.65],"columnData":[36.29,42.98,55.65],"unit":["36.29\u4e07","42.98\u4e07","55.65\u4e07"]},{"name":"\u836f\u54c1\u5236\u9020\u4e1a","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[63.71,57.02,44.35],"columnData":[63.71,57.02,44.35],"unit":["63.71\u4e07","57.02\u4e07","44.35\u4e07"]}],"chartWrap2":[{"name":"\u836f\u54c1\u6d41\u901a-\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-12-31","2016-12-31"],"lineData":[26.71,34.16],"columnData":[26.71,34.16],"unit":["26.71\u4e07","34.16\u4e07"]},{"name":"\u836f\u54c1\u6d41\u901a-\u836f\u54c1","timeData":["2017-12-31","2016-12-31"],"lineData":[11.59,21.49],"columnData":[11.59,21.49],"unit":["11.59\u4e07","21.49\u4e07"]},{"name":"\u836f\u54c1\u5236\u9020-\u5236\u5242\u836f","timeData":["2017-12-31","2016-12-31"],"lineData":[63.71,44.93],"columnData":[63.71,44.93],"unit":["63.71\u4e07","44.93\u4e07"]},{"name":"\u5546\u54c1\u53ca\u6750\u6599\u9500\u552e","timeData":["2017-12-31","2017-06-30"],"lineData":[-2.01,0.31],"columnData":[-2.01,0.31],"unit":["-2.01\u4e07","3100.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-12-31","2016-12-31"],"lineData":[0,-0.54],"columnData":[0,-0.54],"unit":["0.00","-5400"]},{"name":"\u836f\u54c1","timeData":["2017-06-30"],"lineData":[10.47],"columnData":[10.47],"unit":["10.47\u4e07"]},{"name":"\u533b\u7597\u5668\u68b0\u53ca\u8bd5\u5242","timeData":["2017-06-30"],"lineData":[32.2],"columnData":[32.2],"unit":["32.20\u4e07"]},{"name":"\u5236\u5242\u836f","timeData":["2017-06-30"],"lineData":[57.02],"columnData":[57.02],"unit":["57.02\u4e07"]},{"name":"\u836f\u54c1\u5236\u9020-\u539f\u6599\u836f","timeData":["2016-12-31"],"lineData":[-0.04],"columnData":[-0.04],"unit":["-400"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2017-12-31","2017-06-30","2016-12-31"],"lineData":[100,100,100.03],"columnData":[100,100,100.03],"unit":["100.00\u4e07","100.00\u4e07","100.03\u4e07"]},{"name":"\u56fd\u5916","timeData":["2017-12-31","2016-12-31"],"lineData":[0,-0.03],"columnData":[0,-0.03],"unit":["0.00","-300"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 药品流通业 17.17亿 80.47% 15.14亿 96.18% 36.29% 11.83%
药品制造业 4.17亿 19.53% 6010.10万 3.82% 63.71% 85.58%
按产品 药品流通-医疗器械及试剂 8.55亿 40.06% 7.05亿 44.81% 26.71% 17.49%
药品流通-药品 8.42亿 39.48% 7.77亿 49.40% 11.59% 7.70%
药品制造-制剂药 4.17亿 19.53% 6010.10万 3.82% 63.71% 85.58%
商品及材料销售 1983.49万 0.93% 3105.87万 1.97% -2.01% -56.59%
药品制造-原料药 - - - - - -
按地区 国内 21.33亿 100.00% 15.74亿 100.00% 100.00% 26.23%
国外 - - - - - -

董事会经营评述

  一、概述  2017年是医药行业的政策调整期和市场动荡期,随着行业政策和法规制度的陆续出台和持续推进,国内医药行业正驶入规范发展的快车道,同时也面临着新的机遇和挑战。  从行业基本面上来看,医药行业的发展方向已经比较明确。上游原料药行业受环保政策压力影响从而继续清除落后产能,中游制剂研发在政策上实行优化审评、鼓励创新,制剂生产领域持续推进一致性评价工作,实现优胜劣汰和进口替代;下游医药流通两票制持续推进,将促进行业集中度的提升,医院严控药占比、分级诊疗等也将推动医改的持续深化。  报告期内,公司营业收入继续保持稳定增长,资产质量良好,财务状况健康,实现营业收入214,591.81万元,较上... 查看全部▼

  一、概述
  2017年是医药行业的政策调整期和市场动荡期,随着行业政策和法规制度的陆续出台和持续推进,国内医药行业正驶入规范发展的快车道,同时也面临着新的机遇和挑战。
  从行业基本面上来看,医药行业的发展方向已经比较明确。上游原料药行业受环保政策压力影响从而继续清除落后产能,中游制剂研发在政策上实行优化审评、鼓励创新,制剂生产领域持续推进一致性评价工作,实现优胜劣汰和进口替代;下游医药流通两票制持续推进,将促进行业集中度的提升,医院严控药占比、分级诊疗等也将推动医改的持续深化。
  报告期内,公司营业收入继续保持稳定增长,资产质量良好,财务状况健康,实现营业收入214,591.81万元,较上年同比增长3.65%;归属于母公司股东的净利润3,426.10万元,较上年同比增长172.80%。截至2017年底,公司资产总额207,593.76万元,归属于母公司股东的净资产为117,630.54万元,报告期内公司经营活动产生的现金流量净额为-2,633.71万元。

  二、核心竞争力分析
  公司现主要以制剂研发、生产、销售及医药流通等业务为主。研发方面,公司拥有国家级化学合成药物研发技术中心,同时,公司依托北京大学医学院深厚的学术基底以及北大医疗产业集团旗下的方正医药研究院的优势研发资源,共同开展药品研发合作,现已形成丰富的在研产品梯队,将有力保障后续产品供应,助力公司长远发展;此外,制剂营销网络现已基本覆盖全国,并能在新政策形势下顺利进行合规运营;与此同时,公司还拥有分别以北京、湖北地区为核心的医药商业流通中心,其深度分销和配送服务已积蓄了丰富的经验和资源网络,其中,北医医药定位于服务北大医疗产业集团优势医疗资源的集采平台,并和武汉叶开泰均已形成成熟的盈利模式。
  公司"创新、责任、信任、努力"的文化,已成为推动各项工作的核心导向,公司综合竞争力得到进一步提升。
  公司将充分利用北京大学的品牌和资源,集中力量专注制剂研发、生产及销售,加强公司内生增长并适时推进外延发展,最终实现公司的战略目标。

  三、公司未来发展的展望
  2017年,北大医药集中精力,整合资源,最终实现营业收入和净利润的双增长。公司将继续依托北京大学医学部和北大医疗的优势资源,秉承传统与创新,专注于先进的医药研发与制造,优化北京和武汉流通配送体系,促进医药与医疗资源价值最大化,更以推动中国健康产业发展、实现大众健康美好生活为责任使命。
  2017年北大医疗在重新分析市场趋势、竞争格局和国际化进程的基础上,确定了"医疗服务+创新创投+医药工业"三轮驱动的新战略。本次战略调整将医药工业提升到了与医疗服务同一个战略高度。
  着眼未来,用五年左右的时间,北大医疗将打造成具备现代化医院管理输出能力和新技术创新孵化能力,构建完善的互联网医疗和健康险体系,在制药领域具备创新研发能力的国际化大健康龙头企业。因此,根据新战略,北大医疗产业集团将坚定不移地支持北大医药发展,在新一轮行业政策导引下,公司将不断思考与调整,认清自身禀赋,聚焦优势品种,利用好上市公司的品牌优势,逐步打造医药创新能力,把医药工业做大做强。
  1、2018年经营计划
  2018年是国内化学制药企业较为关键的一年,公司将密切关注行业政策动态、提升危机意识和竞争理念,集中力量整合优势资源,并在现有战略目标和方向的基础上进行战略调整和更新,以保障公司实现可持续发展,此外,力争2018年公司主营业务收入和净利润取得更好成绩。
  (1)生产质量:CFDA规定,到2018年底,289基药目录中的固体口服制剂产品需要通过一致性评价,这必然对制药企业提出了更高的生产要求,公司将一如既往地重视生产质量,确保生产的产品符合国家相关法规及相关部门的要求。
  (2)研发:公司持续与方正医药研究院进行紧密联系与项目合作,一方面重点推进仿制药研发项目,积极推进取得产品批文,进一步丰富公司的研发管线和产品布局;另一方面持续关注新型制剂技术的应用与创新,积极筹划搭建缓控释制剂技术平台,力争取得突破性进展和成果。
  (3)营销:2017年全国开始实行"两票制",2018年将是全面执行的一年,公司在营销工作中,还要继续做好应对"两票制"的合法合规工作,搭建具有影响力的学术平台和市场准入平台,确保公司产品进入更多的省级医保目录,继续推进重点产品的销售上量,维持其它产品的稳定销售额。
  (4)流通:公司将根据战略定位,稳定并推进武汉公司的配送业务,维持并推进北京北医医药的供应链管理业务,同时拓展北京和湖北两地的商业网络渠道,扩大集中配送或医药药房托管的销售规模。
  (5)运营管理:继续推进公司信息化系统的建设,实现全面预算管理信息化系统的上线,提高工作效率;采供方面将紧紧围绕公司"降本增效"的目标来开展工作,保障物资按时、按质、按量到厂,同时加强优化渠道工作,寻求更优质的渠道,实现公司业务持续、快速发展。最终努力成为一家盈利显著并具有影响力的上市企业。
  以上经营计划并不构成公司对投资者的业绩承诺,敬请广大投资者注意风险。
  2、可能面对的风险及应对措施
  (1)质量控制风险
  仿制药一致性评价等相关法规政策的持续执行,对国内仿制药质量提出了更高的要求,同时也对药品研发、生产质量等流程提出了新的标准,一致性评价工作需要大量人力、物力和财力的投入,产品在规定期限内是否能够通过新标准还存在较大的不确定性。公司将严格按照GMP规范要求,建立全流程质量把控,认真完成仿制药一致性评价工作,切实保障药品质量,建立良好的信誉与口碑。
  (2)药品降价风险
  近年来受医保控费、降低药占比等因素的影响,各地招投标价格下降压力越来越大,从而也加大了公司中标价降低的风险,对公司发展有不利影响。针对药品降价风险,公司将通过补充后续新产品、加大对现有产品的市场推广力度来提升市场竞争力;与此同时,公司将积极关注产品引进和企业并购机会,并加大研发的力度和投入,以获取新的产品扩大销售规模。
  (3)药品招标政策风险
  2017年,新版国家医保目录落地,但各省份医保增补目录确定和执行情况尚不完全明确,公司招投标难度加大,药品未竞标成功将对公司业绩有不利影响。为减少相关风险,公司将努力推进现有产品进入各省份医保目录的增补工作,并加大产品学术推广力度,加强市场准入工作,力争产品在更多省份实现中标。
  (4)制剂研发风险
  制药行业具有高投入、长周期、高风险的特点,药品从药学研究、临床研究、获取药品注册批件,再到正式生产需要经过多重审批,在此过程中,任一环节的决策与技术出现问题必将会影响研发成果,因此存在不确定性风险。几年来,国家对药品注册监管日趋严格,进而增加了公司的研发风险。为减少研发的风险,公司在项目筛选上将加强立项把关,以市场容量大,制剂工艺成熟的仿制药为主。同时,积极跟踪国家政策导向,积极搭建高水平的研发团队,扎实做好研究工作。
  (5)管理风险
  随着公司转型初显成效,公司的管理与运营能力需要不断加强。在战略定位、资源整合、研发创新、制度调整等方面,公司同样面临更高的要求。公司在管理模式、激励机制、内部控制等方面若无法满足当下医药行业变革的要求,将会在内外部压力下承担更多风险。因此,公司将密切关注行业政策动向,适时进行战略更新,推进精细化管理,持续完善内控体系建设,建立良好的企业文化和激励机制,激活组织活力,借助信息化系统,全面提升组织运营管理能力和管控水平。 收起▲